Overview

A Study to Evaluate the Safety and Efficacy of CLS006 Versus Vehicle in Subjects 2 Years of Age or Older With Cutaneous Common Warts

Status:
Completed
Trial end date:
2018-11-07
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy and safety of six (6) weeks of once daily application of Furosemide Topical Gel 0.125% (CLS006) compared to vehicle in subjects ≥ 2 years of age with nongenital cutaneous common warts (verruca vulgaris).
Phase:
Phase 3
Details
Lead Sponsor:
Cutanea Life Sciences, Inc.
Maruho Co., Ltd.